DANVILLE, Pa., May 10, 2024
/PRNewswire/ -- Cardiologist Brendan Carry, MD, and a team of
Geisinger physicians have enrolled the first patient in the U.S.
into a cardiac amyloidosis trial. The team is also the first to in
the U.S. to screen for the trial.
"If a patient qualifies for the clinical trial, it will allow us
to provide a treatment option when they receive an amyloidosis
diagnosis without having to travel outside of the region for care,"
said Dr. Carry. "Geisinger is at the forefront of research and
technological advancements that allow for better patient outcomes
and improvements in their quality of life."
Cardiac amyloidosis is caused by protein buildup between
the muscle cells of the heart, increasing the thickness of the
heart. As these proteins build up, the heart becomes thicker and
struggles to pump blood. Over time as the heart thickens, heart
failure develops.
Patients with amyloidosis can inherit it from their parents
or develop the condition on their own. Signs include common heart
failure symptoms, such as swelling in the extremities, increased
shortness of breath and weight gain. Patients may also have
neuropathy symptoms, weakness, difficulty walking, tingling or
numbness in their limbs, a decrease in blood pressure when
adjusting positions and carpal tunnel syndrome.
The trial is a phase 3, randomized, double-blind,
placebo-controlled study that evaluates the safety and
effectiveness of amyloid deplete ALXN2220 in participants with
transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).
To be considered for the trial, patients must be between the
ages of 18 to 90, have a confirmed diagnosis of ATTR-CM with
transthyretin that is either wild-type TTR or a variant TR
genotype, and have not received prior treatment with an ATTR
amyloid depleter.
This clinical trial is sponsored by Alexion Pharmaceuticals
Inc.
To learn more or to see if you qualify for this clinical trial,
call 570-214-1991.
About Geisinger
Geisinger is among the nation's
leading providers of value-based care, serving 1.2 million people
in urban and rural communities across Pennsylvania. Founded in 1915 by
philanthropist Abigail Geisinger,
the non-profit system generates $10
billion in annual revenues across 134 care sites - including
10 hospital campuses, and Geisinger Health Plan, with 600,000
members in commercial and government plans. The Geisinger College
of Health Sciences educates more than 5,000 medical professionals
annually and conducts more than 1,400 clinical research studies.
With 26,000 employees, including 1,600 employed physicians,
Geisinger is among Pennsylvania's
largest employers with an estimated economic impact of $14 billion to the state's economy. On
March 31, 2024, Geisinger became the
first member of Risant Health, a new nonprofit charitable
organization created to expand and accelerate value-based care
across the country. Learn more at geisinger.org or follow on
Facebook, Instagram, LinkedIn and X.
CONTACT: Randi Hines
(717)
725-0529
rhines1@geisinger.edu
View original content to download
multimedia:https://www.prnewswire.com/news-releases/geisinger-enrolls-first-patient-in-amyloid-cardiomyopathy-trial-302142357.html
SOURCE Geisinger